Scholarlink

Purpose of Review <p>Metastasis directed therapy (MDT) in the form of stereotactic ablative radiotherapy has been increasingly incorporated in the management of patients with limited systemic metastases. Oligometastatic breast cancer (OMBC) remains a biologically distinct entity within this landscape. Given the increasing prevalence of OMBC, we sought to synthesize the current evidence to guide clinical decision making for these patients.</p> Recent Findings <p>A number of recent studies have been conducted to refine the classification of OMBC, use of MDT, biological considerations, patient selection and clinical integration of focal therapy.&#xa0;</p> Summary <p> The evidence reviewed illustrates the distinctive challenges and opportunities surrounding the use of MDT in the OMBC population. Use of MDT in patients with metachronous lesions may enable continuation of current systemic therapy. Patients with synchronous disease may represent a subgroup in which long term control is possible. Further study is required to identify those that benefit most from MDT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Battleground Oligo: Role for Radiation and Sequencing Amidst an Evolving Systemic Landscape

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • N. Lalani,
  • M. Sun,
  • R. B. Jimenez

摘要

Purpose of Review

Metastasis directed therapy (MDT) in the form of stereotactic ablative radiotherapy has been increasingly incorporated in the management of patients with limited systemic metastases. Oligometastatic breast cancer (OMBC) remains a biologically distinct entity within this landscape. Given the increasing prevalence of OMBC, we sought to synthesize the current evidence to guide clinical decision making for these patients.

Recent Findings

A number of recent studies have been conducted to refine the classification of OMBC, use of MDT, biological considerations, patient selection and clinical integration of focal therapy. 

Summary

The evidence reviewed illustrates the distinctive challenges and opportunities surrounding the use of MDT in the OMBC population. Use of MDT in patients with metachronous lesions may enable continuation of current systemic therapy. Patients with synchronous disease may represent a subgroup in which long term control is possible. Further study is required to identify those that benefit most from MDT.